Haemonetics Corporation (HAE)

Over the last six months, Haemonetics' shares have experienced a decline, sinking to $51.21 and resulting in an 18.2% loss. On August 7, 2025, Haemonetics reported its Q1 FY2026 financial results, with non-GAAP profit beating estimates but GAAP revenue falling short, leading to a 24% stock drop. In October 2025, Citigroup lowered Haemonetics' price target, and Zacks Research cut FY2028 and Q1 EPS estimates. The stock reached new 12-month lows on October 3rd and September 25th, 2025. On May 8, 2025, the company beat Wall Street's revenue expectations in Q1 CY2025, but sales still fell by 3.7% year-on-year to $330.6 million.

The demand for blood and plasma products is generally considered relatively stable, driven by ongoing healthcare needs and advancements in medical treatments. However, recent financial reports suggest potential demand challenges, with analysts expecting a revenue decline of 1.8% over the next 12 months. Legacy products in cardiology have seen slower demand, and the company's organic revenue growth has slowed, suggesting a need to improve products, pricing, or go-to-market strategy.

Haemonetics Corporation is a global healthcare company specializing in blood management solutions, operating within the Medical Devices, Computer Software, Healthcare, and Blood Banking sectors. The company develops and provides devices, information management, and consulting services across the blood supply chain, serving plasma and blood collectors, as well as hospitals. Its major products are categorized into Donor Products, including automated plasma collection systems and donor management software, and Patient Products, including surgical blood salvage devices, hemostasis diagnostic systems, and transfusion management software.

Haemonetics Corporation has a significant global presence, with offices in 16 countries and marketing its products in over 50 countries. The company's revenue is derived nearly equally from its three major markets: Asia, Europe, and the Americas. Its corporate headquarters are in Boston, Massachusetts, USA, with international headquarters in Nyon, Switzerland, and Far Eastern headquarters in Tokyo, Japan. Almost half of its revenues are derived from the Americas.

Haemonetics has historically earned a solid reputation for product innovation, technical expertise, and operational excellence, focusing on "Saving lives through blood management" and "Innovation in healthcare". There haven't been widely publicized major events that have significantly impacted Haemonetics Corp.'s brand reputation in a negative way in the past year. However, recent stock performance and analyst downgrades could indirectly affect investor and market perception of the company's financial health and future prospects.

Haemonetics Corporation is a publicly traded company with ownership distributed among institutional investors, individual investors, and company insiders. Institutional investors hold a significant percentage of shares, with major owners including BlackRock, Inc., Vanguard Group Inc, and Neuberger Berman Group LLC. Individual investors hold a smaller portion, while company executives and board members also hold shares.